{"id":"W4397008063","doi":"10.1016/j.esmoop.2024.103019","title":"10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Institute on the Environment, University of Minnesota; Veracyte; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Eisai; Astellas Pharma; Oncolytics Biotech; Relay Therapeutics; Seagen; MacroGenics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sanofi; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Biomarker; Neoadjuvant therapy; Oncology; Endocrine system; Mutation; Internal medicine; Medicine; Biology; Cancer; Genetics; Hormone; Breast cancer; Gene","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001897667,0.000454437,0.001028426,0.0002220866,0.0001914461,0.0007669379,0.0003021994,0.0004927323,0.001524158],"category_scores_gemma":[0.0018479,0.0002156157,0.0006448747,0.0002369581,0.0004147071,0.0004723173,0.0004370316,0.0008786864,0.0003536307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003935737,"about_ca_system_score_gemma":0.000280662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001899743,"about_ca_topic_score_gemma":0.0003629077,"domain_scores_codex":[0.9993548,0.0003442275,0.00003276506,0.0001207905,0.00008386647,0.0000635209],"domain_scores_gemma":[0.9991311,0.000284791,0.000252318,0.0001029355,0.00004118744,0.00018765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6284006,0.00463683,0.276638,0.0004281477,0.00275387,0.00034711,0.0003335645,0.001740584,0.02244809,0.0002612339,0.00191443,0.06009747],"study_design_scores_gemma":[0.08777392,0.1140468,0.7743101,0.0001057915,0.003887472,0.001197915,0.0002494635,0.003793841,0.006426284,0.0006262554,0.007424021,0.0001581332],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979983,0.0006511242,0.00006563082,0.0001095024,0.00001201629,0.00004919663,0.0002513908,0.000007025501,0.0008557996],"genre_scores_gemma":[0.9977682,0.0002124676,0.0001869274,0.0001424016,0.00005361524,0.0001058015,0.0008428428,0.000005418491,0.0006822881],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001897667,"threshold_uncertainty_score":0.01003593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04233489190041899,"score_gpt":0.3595692542732487,"score_spread":0.3172343623728297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}